|2.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
|3.||Renal Cell Carcinoma (Grawitz Tumor)
|4.||Sarcoma (Soft Tissue Sarcoma)
|5.||Neoplasm Metastasis (Metastasis)
|1.||Demetri, George D: 46 articles (10/2015 - 01/2002)|
|2.||Heinrich, Michael C: 43 articles (09/2015 - 03/2002)|
|3.||Fletcher, Jonathan A: 41 articles (08/2015 - 08/2002)|
|4.||Debiec-Rychter, Maria: 36 articles (09/2015 - 08/2004)|
|5.||Blay, Jean-Yves: 34 articles (01/2016 - 08/2004)|
|6.||Antonescu, Cristina R: 33 articles (08/2015 - 08/2002)|
|7.||von Mehren, Margaret: 32 articles (01/2015 - 08/2002)|
|8.||Trent, Jonathan C: 31 articles (07/2015 - 12/2003)|
|9.||Corless, Christopher L: 30 articles (03/2015 - 03/2002)|
|10.||Nishida, Toshirou: 29 articles (11/2015 - 01/2003)|
|1.||imatinib (Gleevec)FDA Link
06/01/2015 - "The prognosis of advanced gastrointestinal stromal tumors (GISTs) was dramatically improved in the era of imatinib. "
09/01/2010 - "Surgical removal or treatment with Imatinib mesylate (STI-571/Gleevec) is shown to be highly effective in gastrointestinal stromal tumors (GISTs). "
08/01/2009 - "Despite initial efficacy of imatinib mesylate in most gastrointestinal stromal tumor (GIST) patients, many experience primary/secondary drug resistance. "
01/01/2006 - "Although most patients with gastrointestinal stromal tumor (GIST) treated with imatinib mesylate achieve remission or disease stabilization, a significant proportion show progressive disease (PD) with or without initial favorable responses. "
12/01/2003 - "Although complete responses have seldom been seen up until now, imatinib has proven to be extremely effective in the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumors."
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/01/2003 - "Activated receptor-associated tyrosine kinase c-kit, mutated in most gastrointestinal stromal tumors, has proven a clinically effective target for enzyme inhibition. "
11/01/2014 - "Despite significant improvement in survival of gastrointestinal stromal tumors (GIST) due to use of tyrosine kinase inhibitors, surgery still represents the important part of clinical management. "
01/01/2008 - "Tyrosine kinase inhibitors have been shown to have marked clinical efficacy in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). "
06/01/2012 - "Tyrosine kinase inhibitor (TKI) therapy for patients with gastrointestinal stromal tumors (GISTs) has been shown to improve overall outcomes. "
05/01/2013 - "Gastrointestinal stromal tumors (GISTs) can be effectively treated with tyrosine kinase inhibitors (TKIs). "
|3.||sunitinib (Sutent)FDA Link
06/01/2013 - "Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience."
11/01/2015 - "Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor."
05/01/2015 - "Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib."
10/01/2014 - "Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study."
10/01/2010 - "The aim of this review is to gather the preclinical rationale behind the clinical use of sunitinib in gastrointestinal malignancies other than gastrointestinal stromal tumors (GIST) and to summarize the clinical data from phase I to III trials currently available."
11/01/2009 - "A diagnosis of gastrointestinal stromal tumor was ruled out by an oncogenic kinase gene mutation study. "
05/01/2009 - "This study analyzed the relationship between treatment outcome and kinase mutational status in Korean patients with advanced gastrointestinal stromal tumors (GISTs). "
12/01/2006 - "Gastrointestinal stromal tumors (GISTs) represent a distinct oncogenetic entity that is now center stage in clinical trials of kinase-targeted therapies. "
09/15/2004 - "Once a poorly defined pathologic oddity, in recent years, gastrointestinal stromal tumor (GIST) has emerged as a distinct oncogenetic entity that is now center stage in clinical trials of kinase-targeted therapies. "
01/01/2015 - "Kinase genotype analysis of gastric gastrointestinal stromal tumor cytology samples using targeted next-generation sequencing."
|5.||4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)FDA Link
01/01/2015 - "Are Rogerofenib and Nilotinib Effective for Advanced Gastrointestinal Stromal Tumor (GIST) Patients who have Already been Given Main Treatments?"
06/01/2012 - "Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors."
10/15/2011 - "Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor."
09/01/2013 - "Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?"
05/01/2011 - "Efficacy and tolerability of nilotinib in patients with refractory gastrointestinal stromal tumor are briefly discussed."
|6.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
05/01/2011 - "To study the immunophenotype and c-kit or platelet derived growth factor receptor alpha (PDGFRA) gene mutations in CD117-negative gastrointestinal stromal tumors (GISTs). "
09/01/2008 - "To analyze the frequency and spectrum of KIT and platelet-derived growth factor receptor-alpha (PDGFRA) gene in a large series of study and to explore the clinical implication of mutations in the gastrointestinal stromal tumors (GISTs) in China. "
06/01/2006 - "The goal of this study was to investigate the association of mutations in the KIT gene and the platelet-derived growth factor receptor alpha (PDGFRA) gene with clinicopathological features of patients with gastrointestinal stromal tumor (GIST) localized in the stomach. "
09/01/2015 - "Gastrointestinal stromal tumors (GISTs) were originally thought to harbor either KIT or platelet-derived growth factor receptor A (PDGFRA) mutations only. "
08/01/2015 - "Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1."
|7.||Tyrosine (L-Tyrosine)FDA Link
01/01/2015 - "Regorafenib is a small molecule inhibitor of tyrosine kinases, and has been shown to improve the outcomes of patients with advanced colorectal cancer and advanced gastrointestinal stromal tumors. "
10/01/2013 - "Gastrointestinal stromal tumors (GISTs) are unique tumors, arising largely due to oncogenic mutations in KIT or PDGFRA tyrosine kinases. "
06/01/2013 - "Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of gastrointestinal tract and are characterized by presence of mutations in tyrosine kinases cKIT (KIT) and PDGFRα (PDGFRA). "
04/01/2004 - "Constitutively activated tyrosine kinases have been identified as major pathogenetic mechanisms in the development of malignant diseases like gastrointestinal stromal tumors (c-kit) and chronic myelogenous leukemia (bcr-abl). "
02/04/2009 - "Chronic myeloid leukemia, gastrointestinal stromal tumors (GISTs), and idiopathic hypereosinophilic syndrome are associated with pathological deregulation of the tyrosine kinases BCR-ABL, KIT, and PDGFRA, respectively. "
|8.||dasatinib (BMS 354825)FDA Link
09/01/2010 - "Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib."
05/28/2015 - "Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells."
05/28/2015 - "Dasatinib-based therapy is often used as a second-line therapeutic strategy for imatinib-resistance gastrointestinal stromal tumors (GISTs); however, acquired aberrant activation of dasatinib target proteins, such as c-KIT and PDGFRβ, attenuates the therapeutic efficiency of dasatinib. "
09/15/2008 - "Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation."
08/01/2007 - "Novel tyrosine kinase inhibitors such as imatinib, nilotinib and dasatinib, have been found to be effective in the management of various subtypes of systemic mastocytosis and gastrointestinal stromal tumors. "
|9.||tyrosine receptor (receptor, tyrosine)IBA
10/01/2011 - "Targeted therapy based on the inhibition of the receptor tyrosine kinases has improved the outcome of patients with metastatic, recurrent and/or unresectable gastrointestinal stromal tumors (GIST). "
03/01/2015 - "Gastrointestinal stromal tumor (GIST), originating from the interstitial cells of Cajal (ICC), is characterized by frequent activating mutations of the KIT receptor tyrosine kinase. "
02/06/2015 - "Mutations in the Kit receptor tyrosine kinase gene (KIT), which result in constitutive activation of the protein (KIT), are causally related to the development of gastrointestinal stromal tumors (GISTs). "
01/01/2015 - "Gastrointestinal stromal tumors, which are thought to derive from interstitial cells of Cajal or their precursors, often harbor an oncogenic mutation of the KIT receptor tyrosine kinase. "
11/01/2014 - "The successful treatment of advanced gastrointestinal stromal tumors (GIST) with receptor tyrosine kinase (RTK) inhibitors has raised the hope that other malignancies could also benefit from a similar treatment. "
02/15/2005 - "Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden."
04/01/2012 - "In the last decade, the introduction of imatinib mesilate into the clinical practice has resulted in a dramatic improvement in the treatment of gastrointestinal stromal tumor (GIST). "
11/01/2010 - "[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects]."
06/01/2009 - "[A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate]."
06/01/2009 - "We report a patient who long had a complete response by chemotherapy with imatinib mesilate(IM)for locally recurrent gastrointestinal stromal tumor(GIST)of the stomach. "
|1.||Drug Therapy (Chemotherapy)
05/01/2009 - "Despite development of novel chemotherapy for gastrointestinal stromal tumors (GISTs), complete resection remains the gold standard treatment. "
08/15/2002 - "Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy."
09/01/2014 - "Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor."
06/01/2012 - "The stomach is the most common site of gastrointestinal stromal tumors (GISTs), but the surgical outcomes of gastric GISTs in the era of targeted drug therapy are unclear. "
06/01/2012 - "Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy."
|2.||Molecular Targeted Therapy
01/01/2015 - "Despite the efficacy of molecular targeted therapy, surgical resection remains the only curative primary treatment for gastrointestinal stromal tumors (GISTs). "
07/01/2005 - "The value of molecular-targeted therapy as an adjuvant for high-risk gastrointestinal stromal tumor patients is a different subject awaiting long-term results of ongoing trials."
09/01/2013 - "In an era of molecular targeted therapy, patients with advanced gastrointestinal stromal tumor (GIST) are living longer and are often followed with imaging. "
07/01/2011 - "Molecular targeted therapy of gastrointestinal stromal tumors."
12/01/2010 - "Unlike novel molecular-targeted therapies for metastatic gastrointestinal stromal tumors (GIST), conventional treatments for peritoneal sarcomatosis (PS) are mostly ineffective. "
|3.||Heterologous Transplantation (Xenotransplantation)
04/01/2015 - "Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models."
04/01/2015 - "We evaluated the efficacy of CK6, a KIT monoclonal antibody, in a panel of human gastrointestinal stromal tumor (GIST) xenograft models. "
01/01/2014 - "Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor."
07/01/2013 - "Establishment and characterization of novel cell lines and xenografts from patients with gastrointestinal stromal tumors."
01/01/2013 - "Establishment and characterization of a novel xenograft model of human gastrointestinal stromal tumor in mice."
01/01/2008 - "[Gastrointestinal stromal tumors: role of computed tomography before and after treatment]."
01/01/2006 - "Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case."
08/01/2009 - "The purpose of this study was to correlate findings on the first follow-up CT after treatment with imatinib in patients with residual or recurrent gastrointestinal stromal tumors (GISTs) with the different types of KIT mutation present at initial resection. "
01/01/2014 - "[Curative resection of an extra-gastrointestinal stromal tumor locally advanced and fistulizing in the small intestine after treatment with imatinib: report of a case]."
07/01/2013 - "[A case of a giant rectal gastrointestinal stromal tumor radically resectable after treatment with neoadjuvant imatinib mesylate]."
01/01/2007 - "Left extended hepatectomy for a metastatic gastrointestinal stromal tumor after a disease-free interval of 17 years: report of a case."
11/01/2012 - "[A case of drug resistant recurrent gastrointestinal stromal tumor treated surgically by resection, partial hepatectomy and diaphragmectomy]."
11/01/2012 - "A 54-year-old woman had previously undergone a partial hepatectomy because of involvement of her liver by a gastrointestinal stromal tumor. "
11/01/2007 - "Effect of loss of heterozygosity of the c-kit gene on prognosis after hepatectomy for metastatic liver gastrointestinal stromal tumors."
01/01/2003 - "The utility of hepatectomy for patients with metastatic liver tumors from gastrointestinal stromal tumors (GISTs) was evaluated in the present study. "